Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

The Top 5 Biosimilar Articles for the Week of June 10

June 14th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 10, 2024.

Switch to Adalimumab Biosimilar Safe, Effective for Uveitis, but the Nocebo Effect Persists

June 13th 2024

By Cameron Santoro

Article

Switching patients with non-infectious uveitis from originator adalimumab to biosimilar adalimumab-atto was safe and effective, but some patients experienced the nocebo effect, where negative adverse events are caused by patients’ poor perception of the drug rather than the medication itself.

Real-World Study: Nonmedical Switch to Infliximab Biosimilar Is Safe, Effective in Pediatric Patients With IBD

June 12th 2024

By Deana Ferreri, PhD

Article

A real-world study of children and young adults with inflammatory bowel disease (IBD) switched from the infliximab reference product to a biosimilar concluded effectiveness was maintained over 12 months based on stable remission rates and biochemical markers.

New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers

June 11th 2024

By Skylar Jeremias

Article

Posters from the American Society of Clinical Oncology annual meeting showcased safety and efficacy data for a trastuzumab biosimilar and an ado-trastuzumab biosimilar in HER2-positive (HER2+) cancers.

Review Finds 7 Themes That Can Help Define the Value of Biosimilars

June 10th 2024

By Skylar Jeremias

Article

Authors of an integrated literature review identified 7 themes that help stakeholders define the value of biosimilar portfolios beyond cost savings, which could provide stakeholders better clarity as to the value of a biosimilar portfolio vs a single biosimilar within a portfolio.

Dr Lakesha Farmer Highlights Current Biosimilar Education, Acceptance Efforts

June 9th 2024

By Ashley Gallagher

Video

Cencora's Lakesha Farmer, PharmD, MBA, discusses efforts that health care organizations can take to better educate patients and providers on biosimilars to improve biosimilar acceptance and achieve cost savings associated with these products.

Switching Patients With IBD to Infliximab, Adalimumab Biosimilars Did Not Impact Efficacy

June 8th 2024

By Deana Ferreri, PhD

Article

Researchers reviewed real-world evidence on the safety and effectiveness of switching from tumor necrosis factor-α inhibitor originators to biosimilars in inflammatory bowel disease (IBD), prompted by mandatory switching policies in most Canadian provinces.

The Top 5 Biosimilar Articles for the Week of June 3

June 7th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 3, 2024.

Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships

June 6th 2024

By Skylar Jeremias

Article

American and European regulatory agencies have provided companies with good news, with several biosimilar candidates seeing application acceptances or approvals in Europe.

ASCO 2024 Posters Showcase Positive Data on Denosumab, Pegfilgrastim Biosimilars

June 5th 2024

By Skylar Jeremias

Article

Posters from the American Society of Clinical Oncology (ASCO) 2024 annual meeting demonstrate positive safety and efficacy data for denosumab and pegfilgrastim biosimilars.